PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

TransEnterix (Durham, NC) a development-stage medical device company focused on a laparoscopic surgical platform for minimally invasive abdominal surgeries, closed a $55M Series B financing. Participants include Aisling Capital, Intersouth Partners, Quaker BioVentures, SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Centice (Morrisville, NC) developer of a pharmaceutical verification device to improve accuracy of dispensed medications, closed a $6.1M Series C financing. Participants include Fulcrum Financial Group, The Aurora Funds, S-Group Direct Investments, Innovation Ventures and Novak Biddle Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Metabolon (Durham, NC) a metabolomics services and informatics company focused on detection of small molecule biomarkers, closed a $6M Series C financing, bringing the entire financing round to $12.3M. Participants include Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities.

Micell Technologies (Raleigh, NC) a development-stage medical device company focused on a fluid-based drug eluting stents for the interventional cardiology market, closed a $15M Series B financing. Participants to date have included St.Jude Medical, Invemed Catalyst Fund and GE.

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $7M Series C financing. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates and Firelake Capital.

Viamet Pharmaceuticals (Morrisville, NC) a pre-clinical stage pharmaceutical company focused on small-molecule inhibitors of metalloenzymes, closed a $18M Series B financing. Participants include Novartis Option Fund. Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Cempra Pharmaceuticals (Chapel Hill, NC) a clinical-stage company developing antibiotics for difficult-to-treat and drug-resistant infections, closed a $46M Series C financing. Participants include Quaker BioVentures, Devon Park Bioventures, Aisling Capital, Intersouth Partners, Teachers’ Private Capital and I. Wistar Morris III.

nContact Surgical (Morrisville, NC) a development-stage company focused on a cardiac tissue coagulation device intended to treat atrial fibrillation epicardially on a beating heart, closed a $15M Series C financing. Participants include Tall Oaks Capital, Village Ventures, Finistere Partners, Intersouth Partners, Massey Burch Capital, Harbert Venture Partners and Hippo Ventures.
CORRECTION | Previously reported as [...]

Piedmont Pharmaceuticals (Greensboro, NC) a commercial-stage specialty pharma company focused on parasitology and drug delivery systems for human and companion animal use, closed a $5M Series C financing. Participants include CM Capital.

Diagnosoft (Morrisville, NC) an early-stage device company focused on analyzing MRI images of the heart to measure and visualize cardiac muscle function, closed a $4M Series B financing. Participants include Technology Development Fund.